- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
MET Amplification a Viable Screen for NSCLC, Study Claims
A study published in Clinical Cancer Research found that 33% of lung cancer biopsies evaluated had a gain of function amplification in the MET receptor tyrosine kinase.
MET
A third of non-small-cell lung cancers (NSCLCs) show low- to high-level amplification of the gene, according to a German study, with no significant difference in frequency across different types of cancer and genetic backgrounds.
MET
Hans-Ulrich Schildhaus, from University Hospital Göttingen, and colleagues explain that alterations in the expression levels of the MET receptor tyrosine kinase, a potential therapeutic target in lung cancer, can be caused by various mechanisms, of which gene amplification is one.
MET
Highlighting the “controversial” nature of amplification in NSCLC, they used fluorescence in situ hybridisation to assess its prevalence in 693 treatment-naive NSCLC patients, of whom 519 had adenocarcinomas and 174 had squamous cell carcinomas.
MET
MET
MET
MET
Thirty-three percent of the samples included in the study had gains of any level in copy number. Of these 22 (3%) tumours had high-level amplification, defined as fulfilling one of the following criteria:/centromere 7 ratio of at least 2.0; average gene copy number per cell of 6.0 or higher; and/or at least 10% of tumour cells containing 15 or more copies of the gene.
Link to the complete article on medwireNews:
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More
